| A102 |
Lilly patent anti-FGFR-1 Biosimilar(Anti-FGFR1 / CD331 Reference Antibody)
Featured
|
|
|
| A103 |
Aprutumab Biosimilar(Anti-FGFR2 / CD332 Reference Antibody)
Featured
|
Aprutumab (BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research. |
.png)
|
| A104 |
Bemarituzumab Biosimilar(Anti-FGFR2 / CD332 Reference Antibody)
Featured
|
Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. |
.png)
|
| A105 |
Vofatamab Biosimilar(Anti-FGFR3 / CD333 Reference Antibody )
Featured
|
Vofatamab (B-701) is an anti-FGFR3 monoclonal antibody (mAb). Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). |
.png)
|
| A106 |
U3-1784 Biosimilar(Anti-FGFR4 / CD334 Reference Antibody)
Featured
|
|
|
| A107 |
Radretumab Biosimilar(Anti-Fibronectin Reference Antibody)
Featured
|
|
.png)
|
| A109 |
Rosopatamab Biosimilar(Anti-FOLH1 / PSMA Reference Antibody)
Featured
|
Rosopatamab (HuJ591) is a humanized antiPSMA IgG1 monoclonal antibody that can be used in cancer research, especially prostate cancer. Rosopatamab can be linked to the low-energy beta-emitting radioisotope lutetium-177 (177Lu) through the bifunctional chelator DOTA-NHS ester to obtain a radioimmunoconjugate that targets malignant prostate cells with high efficiency. |
.png)
|
| A110 |
Pelgifatamab Biosimilar(Anti-FOLH1 / PSMA Reference Antibody)
Featured
|
Pelgifatamab (BAY-2315497) is a prostate-specific membrane antigen (PSMA) antibody. Pelgifatamab can be covalently linked to a binding moiety of 225Ac and used for metastatic castration-resistant prostate cancer (mCRPC) research. |
.png)
|
| A111 |
Mirvetuximab Biosimilar(Anti-FOLR1 / FRA Reference Antibody)
Featured
|
Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research. |
.png)
|
| A619 |
Sacituzumab govitecan
Featured
|
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity. |
|
| A112 |
Farletuzumab Biosimilar(Anti-FOLR1 / FRA Reference Antibody)
Featured
|
Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer. |
.png)
|
| A114 |
Dompe patent anti-FOLR1 Biosimilar(Anti-FOLR1 / FRA Reference Antibody)
Featured
|
|
|
| A116 |
BMS-986012 Biosimilar（Anti-Fucosyl GM1 Reference Antibody）
Featured
|
|
|
| A130 |
Vantictumab Biosimilar（Anti-FZD Reference Antibody）
Featured
|
Vantictumab (OMP-18R5) is a fully human IgG2 monoclonal antibody. Vantictumab inhibits Wnt pathway signaling by binding to FZD1/2/5/7/8 receptors. Vantictumab is being studied against cancers such as metastatic HER2-negative breast cancer and metastatic pancreatic adenocarcinoma. |
.png)
|
| A131 |
U.Toronto patent anti-FZD7 Biosimilar（Anti-FZD7 Reference Antibody）
Featured
|
|
|
| A132 |
U.Washington patent anti-GAD65 Biosimilar（Anti-GAD65 Reference Antibody）
Featured
|
|
|
| A133 |
Crotedumab Biosimilar（Anti-GCGR Reference Antibody）
Featured
|
Crotedumab (REGN1193) is a fully human IgG4 monoclonal antibody that binds and inhibits glucagon receptor (GCGR), with a KD of 0.1 nM. Crotedumab can be used for the research of diabetes. |
.png)
|
| A134 |
Volagidemab Biosimilar（Anti-GCGR Reference Antibody）
Featured
|
Volagidemab is an antagonistic glucagon receptor (GCGR) monoclonal antibody (mAb). Volagidemab can be used in the research of type 1 diabetes (T1D). |
.png)
|
| A135 |
Naxitamab Biosimilar（Anti-GD2 Reference Antibody）
Featured
|
Naxitamab (Hu3F8) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers. |
.png)
|
| A136 |
Lorukafusp alfa Biosimilar（Anti-GD2 Reference Antibody）
Featured
|
Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity. |
.png)
|
| A137 |
Ecromeximab Biosimilar（Anti-GD3 Reference Antibody）
Featured
|
Ecromeximab (KM 871; KW 2871) is a mouse-derived IgG-κ chimeric antibody targeting ganglioside GD3. Ecromeximab is expressed by YB2/0 rat hybridoma cells. |
.png)
|
| A138 |
Ponsegromab Biosimilar（Anti-GDF15 / MIC1 Reference Antibody）
Featured
|
Ponsegromab (PF 06946860) is a potent and selective humanized anti-GDF15 monoclonal antibody with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers. |
.png)
|
| A139 |
Apitegromab Biosimilar（Anti-GDF8 / Myostatin Reference Antibody）
Featured
|
Apitegromab (SRK-015) is an anti-promyostatin monoclonal antibody. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy. |
.png)
|
| A140 |
Trevogrumab Biosimilar（Anti-GDF8 / Myostatin Reference Antibody）
Featured
|
Trevogrumab (REGN-1033) is a monoclonal antibody targeting GDF8 (growth differentiation factor 8, also known as muscle growth inhibitor). Trevogrumab is used in studies of sarcopenia, including wasting atrophy, chronic diseases, and changes in food and nutritional intake. |
.png)
|
| A141 |
Landogrozumab Biosimilar（Anti-GDF8 / Myostatin Reference Antibody）
Featured
|
Landogrozumab (LY2495655) is an humanized anti-myostatin monoclonal antibody. Landogrozumab effectively improves muscle volume, hand grip strength and function. Landogrozumab can be used for the research of muscle wasting disease. |
.png)
|
| A142 |
Lintuzumab Biosimilar（Anti-Siglec-3 / CD33 Reference Antibody）
Featured
|
Lintuzumab (HUM-195) is an anti-CD33 humanized monoclonal antibody. Lintuzumab reduces the production of TNFα-induced pro-inflammatory cytokines and chemokines by AML cells. Lintuzumab promotes tumor cell killing through antibody-dependent cellular cytotoxicity (ADCC) and phagocytosis (ADCP) activities against MDR? and MDR+ AML cell lines and primary AML patient samples. Lintuzumab enhances survival and reduces tumor burden in mice. |
.png)
|
| A143 |
NGM120 Biosimilar（Anti-GFRAL Reference Antibody）
Featured
|
|
|
| A144 |
Amgen patent anti-GIPR Biosimilar（Anti-GIPR Reference Antibody）
Featured
|
|
|
| A145 |
Centocor patent anti-GLP-1R Biosimilar(Anti-GLP1R Reference Antibody)
Featured
|
|
|
| A146 |
Cureab patent anti-GP73 Biosimilar(Anti-GOLM1 Reference Antibody)
Featured
|
|
|
